Skip to main content
. 2023 May 8;4(3):100204. doi: 10.1016/j.xhgg.2023.100204

Table 1.

Baseline characteristics of the cohorts

Aotearoa NZ discovery cohort
Samoan replication cohorts
Pacific Trust cohort
NZ Māori CI Māori Samoan Tongan Niuēan Pukapukan Other/Mixed Ngāti Porou Hauora Samoan I Samoan II Samoan III All
Participants (n) 814 172 322 155 37 72 232 270 2851 908 550 255
Sex (male) n (%) 459 (56.39) 105 (61.05) 235 (72.98) 117 (75.48) 28 (75.68) 32 (44.44) 143 (61.64) 186 (68.89) 1146 (40.2) 406 (44.7) 252 (45.8) 126 (49.41)
Age range 17–85 18–88 18–81 18–79 19–75 18–84 17–88 18–94 22–65 18–88 29–88 14–25
Age distribution 50.92 ± 15.36 50.97 ± 15.22 44.78 ± 14.18 42.17 ± 14.53 48.78 ± 13.62 44.93 ± 17.2 41.34 ± 15.69 56.15 ± 13.61 45.09 ± 11.18 43.26 ± 16.23 43.46 ± 8.74 18.49 ± 2.54
Height (cm) 170.31 ± 9.9 169.44 ± 10.43 173.57 ± 9.05 174.48 ± 8.65 172.13 ± 8.18 165.44 ± 9.57 171.74 ± 8.21 169.38 ± 8.68 165.2 ± 7.8 166.6 ± 8.1 165.4 ± 7.9 172.11 ± 8.95
Weight (kg) 95.58 ± 23.27 100.26 ± 24.53 106.04 ± 23.74 107.43 ± 20.92 98.49 ± 18.59 95.6 ± 20.4 104.07 ± 28.05 100.17 ± 24.81 91.3 ± 18.9 93.1 ± 22.7 87.6 ± 18.3 87.98 ± 20.28
LDLa (mmol/L) 2.74 ± 0.96 2.89 ± 0.96 2.91 ± 1.03 2.85 ± 1.05 2.89 ± 0.94 2.75 ± 1.1 2.78 ± 0.95 2.95 ± 1.06 3.4 ± 0.86) 3.2 ± 0.90 3.6 ± 0.85 2.36 ± 0.64
HDLa (mmol/L) 1.18 ± 0.4 1.18 ± 0.38 1.12 ± 0.34 1.11 ± 0.37 1.1 ± 0.32 1.21 ± 0.23 1.15 ± 0.37 1.15 ± 0.3 1.2 ± 0.29) 1.1 ± 0.26 1.0 ± 0.28 1.33 ± 0.32
Gout, n (%) 356 (43.95) 91 (52.91) 178 (55.97) 79 (50.97) 24 (64.86) 15 (20.83) 102 (43.97) 170 (62.96) 0 (0.0)
Type 2 diabetes, n (%) 200 (27.47) 53 (33.97) 61 (21.79) 35 (27.13) 7 (24.14) 19 (27.14) 48 (22.64) 62 (23.66) 508 (17.8) 87 (10.1) 0 (0.0)

The proportions with type 2 diabetes and gout are calculated from individuals without missing data.

Data are mean ± standard deviation or n (%), unless otherwise stated.

NZ, New Zealand; CI, Cook Islands.

a

Data were unavailable for lipid-lowering medications.